-

09:19:39 PM

VXRT Stock News

VXRT - Vaxart Inc

10/07/21 4:13 PM

Nasdaq : VXRT

covid-19

New Duke University-led Study Shows That Vaxart's Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model

A Duke University -led study published in bioRxiv showed that Vaxart, Inc.'s (NASDAQ: VXRT) investigational oral tablet vaccine reduced the airborne transmission of SARS-CoV-2 virus in an animal model.These results are consistent with

RHEA-AI

neutral

10/06/21 8:00 AM

Nasdaq : VXRT

clinical trialcovid-19

Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

 Vaxart, Inc. (NASDAQ: VXRT) today announced that it has begun recruiting subjects for its Phase II COVID-19 oral tablet vaccine clinical trial.Vaxart expects to begin dosing the first of 96 U.S. subjects, split evenly between COVID-19

RHEA-AI

neutral

09/27/21 8:00 AM

Nasdaq : VXRT

management

Vaxart Appoints Dr. James F. Cummings as Chief Medical Officer

Vaxart, Inc. (NASDAQ: VXRT), today announced the appointment of James F. Cummings, M.D., as the Company's Chief Medical Officer (CMO). Dr. Cummings is a Board-Certified Infectious Diseases Physician with extensive experience in vaccine,

RHEA-AI

neutral

09/22/21 4:05 PM

Nasdaq : VXRT

conferences

Vaxart To Present at Upcoming Vaccine Conferences

Vaxart, Inc. (NASDAQ: VXRT), today announced that one of the company's senior scientists, Susan Johnson PhD, will present at both ID Week 2021 and the 15 th Vaccine Congress. Dr. Johnson will provide an update on the development of

RHEA-AI

neutral

09/21/21 4:15 PM

Nasdaq : VXRT

management

Vaxart Announces Creation of Manufacturing and Quality Advisory Board

Vaxart, Inc. (NASDAQ: VXRT), today announced that it has formed a Manufacturing and Quality Advisory Board."We are very excited to be able to tap into the vast knowledge of this group of experts," said Andrei Floroiu, Vaxart's Chief

RHEA-AI

positive

09/20/21 8:00 AM

Nasdaq : VXRT

conferences

Vaxart to Present at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30

Vaxart, Inc. (NASDAQ: VXRT) today announced that Chief Executive Officer Andrei Floroiu and Chief Scientific Officer Dr. Sean Tucker will present at the 2021 Cantor Virtual Global Healthcare Conference at 10:40 a.m. ET on Thursday, September 30,

RHEA-AI

neutral

09/07/21 4:20 PM

Nasdaq : VXRT

conferences

Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and CEO, and Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the H.C. Wainwright 23 rd Annual Global Investor Conference taking place Sept. 13-15,

RHEA-AI

neutral

08/23/21 9:00 AM

Nasdaq : VXRT

management

Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors

Vaxart, Inc. (NASDAQ: VXRT) today announced the addition of Julie M. Cherrington, Ph.D., to the company's board of directors. Dr. Cherrington is an experienced life science executive with extensive insights into taking drugs through the

RHEA-AI

very positive

08/19/21 4:02 PM

Nasdaq : VXRT

management

Vaxart Announces Creation of New Scientific and Clinical Advisory Board

Vaxart, Inc. (NASDAQ: VXRT), today announced the creation of an eight-member Scientific and Clinical Advisory Board.The Advisory Board, whose first meeting occurred on July 24, 2021, is comprised of medical and health care professionals

RHEA-AI

very positive

08/05/21 4:02 PM

Nasdaq : VXRT

earnings

Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results

Vaxart, Inc. (Nasdaq: VXRT) issued its business update today for the second quarter of 2021, reporting strong forward momentum in development of oral tablet vaccines that it believes can revolutionize public health.Vaxart, a clinical-stage

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

VXRT Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websitevaxart.com
Security nameVaxart Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees28
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

VXRT Description:

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.